<?xml version="1.0" encoding="utf-8"?>
<root>
  <passage>
    <infon key="section_type">TITLE</infon>
    <text>In-vivo evaluation of simultaneous administration of incompatible 		  drugs in a central venous catheter with a decreased port to port distance</text>
  </passage>
  <passage>
    <infon key="section_type">ABSTRACT</infon>
    <text>The use of a triple-lumen catheter with 0.4cm of space between the proximal port and the medial port, and 1.3 cm of distance between them and their distal port in order to administer incompatible solutions does not lead to adverse clinical effects.</text>
  </passage>
  <passage>
    <infon key="section_type">INTRO</infon>
    <text>The interaction between the MS2 coat protein and its translational operator is a well-established example of RNA-protein recognition, utilizing genetic, biochemical, and structural methods. Figure 1 displays the primary and secondary structures of the recombinant rRNA hairpin that establish contacts with both subunits of each coat proteins dimer. The coat protein complex with its RNA target is highly intricate, as two unpaired adenosines are inserted into equivalent pockets on different subunits of the coat dimer (Figure 2). The interactions between A-4 and A-10 with coat proteins involve non-identical contacts with the same five amino acid residues, Val29, Thr45, Ser47, Finally, and Lys61. The use of X-ray crystallographic analysis indicates specific amino acid-nucleotide interactions, but fails to provide a clear explanation of their respective roles in RNA-binding and translational repression. In the experiments described here, we used amino acid substitutions of A-pocket amino acids in single-chain coat protein heterodimers to determine the significance of each residue's interaction with A-4 and A-10.</text>
  </passage>
  <passage>
    <infon key="section_type">CONCL</infon>
    <text>Antibiotic policy in the SouthEast varies greatly depending on the structure and content of the regulations. The aim of this review is to revise current recommendations and maintain an effective range of antibiotics. The implementation of policies alone is insufficient to accomplish this. Instead, it requires local ownership by all prescribers and effective monitoring to ensure compliance with the local antibiotic policy. Perhaps the most critical task is to build an evidence base that can support not only the content of these policies but also their implementation and use. All individuals should be able to benefit from the actions being carried out by a suitable national group.</text>
  </passage>
</root>
